Minerva Neurosciences, Inc.

    Jurisdiction
    United States
    LEI
    54930017PANCHC5LYH79
    ISIN
    US6033802058 (NERV)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Read full profile

    Fundamentals

    Net revenue
    €36.01K
    Gross margin
    15.1%
    EBIT
    -€15.81M
    EBIT margin
    -43,917.6%
    Net income
    €5.76M
    Net margin
    15,987.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 114K $193.97K -14K Sell

    Earnings Calls

    Latest earnings call: May 15, 2023 (Q1 2023)

    Add to watchlist

    Notifications